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N-acetyl aspartate concentration in the anterior cingulate 
cortex in patients with schizophrenia: a study of clinical and 
neuropsychological correlates and preliminary exploration of 
Cognitive Behaviour Therapy effects 
Abstract 
This study investigated the clinical and neuropsychological correlates of N-acetyl 
aspartate (NAA) concentration in the anterior cingulate cortex (ACC) in 
schizophrenia, and explored whether ACC NAA concentration is sensitive to 
symptom change following cognitive behaviour therapy for psychosis (CBTp). Thirty 
patients and 15 healthy controls underwent magnetic resonance spectroscopy of the 
ACC and were assessed on frontal-lobe based neuropsychological tasks. Twenty-
four (of 30) patients were followed-up; 11 subsequently received 8-9 months of CBTp 
in addition to standard care (CBTp+SC) and 13 received SC only. At baseline (i) 
NAA and Cr concentrations were lower in patients compared to controls, (ii) in 
patients, NAA concentration correlated inversely with positive symptoms and general 
psychopathology (positive symptoms explained 21% of the variance; total variance 
explained=25%) and Cho concentration correlated inversely with positive symptoms, 
and (iii) in controls, NAA concentration correlated positively with working and short-
term memory and Cr concentration inversely with executive function. NAA 
concentration tended to increase in CBTp+SC patients at follow-up (n=7 with usable 
data) concomitant with improvement in positive symptoms. NAA concentration may 
be more closely associated with symptoms and symptom change than frontal-lobe 
based neuropsychological functions in schizophrenia, perhaps because the latter is 
relatively stable during the long-term illness course. 
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1. Introduction 
Schizophrenia is often characterised by a profile of clinical and neuropsychological 
impairment that is consistent with a frontal lobe-based pathology (Weinberger et al., 
1994). Structurally, grey matter (GM) reduction in the anterior cingulate cortex (ACC) 
has been observed in patients with schizophrenia (Baiano et al., 2007; Fornito et al., 
2008), though such reductions are not limited to the ACC (see Honea et al., 2005 for 
a meta-analytic review of GM reductions in schizophrenia). 
A further mode of investigating the neuropathology of schizophrenia is at the 
neurochemical level. N-acetyl aspartate (NAA) loss and impaired mitochondrial 
function are characteristic of several neurodegenerative diseases, including 
Alzheimer's Disease and multiple sclerosis (Perry et al., 2002; Rutten et al., 2003). 
These findings suggest that NAA concentration may be an indicator of mitochondrial 
function. N-methyl D-aspartate (NMDA) receptor activation coupled with Ca2+ 
cellular influx has been reported to increase neuronal release of NAA and delay 
nerve cell death (Tranberg et al., 2004). NAA concentration thus may also be an 
indicator of NMDA function and neuronal longevity. Interestingly, NMDA glutamate 
receptor dysfunction has been suggested to sub-serve many abnormalities 
associated with schizophrenia (Moghaddam, 2003). It has been reported that 
inhibitors of NMDA function, such as phencyclidine or ketamine, precipitate 
symptoms of schizophrenia in healthy people and exacerbate symptoms in patients 
with schizophrenia (Adler et al., 1999; Krystal et al., 1994; Lahti et al., 1995; Malhotra 
et al., 1997). Ketamine is also found to cause disruptions in working memory in both 
healthy and schizophrenia populations (Adler et al., 1999), indicating that deficient 
activation of NMDA receptors may be crucially involved in neuropsychological deficits 
commonly observed in patients with schizophrenia. Choline (Cho) and 
creatine/phosphocreatine (Cr) concentrations may also be important to neuronal 
integrity. Cho is involved in the synthesis of membrane phospholipids (Ross and 
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Sachdev, 2004, review), while Cr helps maintain the energy homeostasis within the 
nerve cell (Andres et al., 2008). The evidence suggests that Cr may also have direct 
effects on neuropsychological function. For example, oral supplements of Cr 
increased intelligence, working memory performance (Rae et al., 2003) and 
executive function (McMorris et al., 2007; McMorris et al., 2006). 
Previous studies have reported, using magnetic resonance spectroscopy (MRS), 
lower ACC NAA level in patients with schizophrenia, especially in those treated with 
typical antipsychotic drugs, compared to healthy participants (Braus et al., 2002; 
Deicken et al., 2000; Ende et al., 2000; Sanches et al., 2008; Tayoshi et al., 2009; 
Wood et al., 2007; Yamasue et al., 2002; see Appendix 1 for detailed information). 
Within this patient population, ACC NAA concentration is reported to be inversely 
associated with illness duration in some studies (Braus et al., 2002; Ende et al., 
2000; Theberge et al., 2003), but not others (Deicken et al., 1997; Tayoshi et al., 
2009; Theberge et al., 2004; Wood et al., 2007; Yamasue et al., 2002). NAA 
reductions have been reported in antipsychotic drug-naive first-episode patients and 
treatment may increase NAA levels in both recent-onset cases and patients with 
chronic illness (Braus et al., 2002; Fannon et al., 2003). NAA concentration is 
positively associated with duration on atypical antipsychotic medication in long-term 
patients (Braus et al., 2002), and inversely correlated with the duration of positive 
symptoms in first-episode neuroleptic-naive patients (Theberge et al., 2004). More 
recently, Tayoshi and colleagues (2009) observed no association between NAA 
concentration and symptoms, but reported a positive association between NAA 
concentration and Wisconsin Card Sorting Test (WCST) performance; the latter 
finding was also present in two earlier studies (Braus et al., 2002; Ohrmann et al., 
2008). 
Neuropsychological^, the ACC is involved in components of the central executive 
that facilitate working memory (Osaka et al., 2004; Smith and Jonides, 1999), 
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including encoding of semantic information (Kaneda and Osaka, 2008), and reported 
to be deactivated in schizophrenia patients compared to healthy participants during 
the stimulus encoding phase of a working memory task (Schlosser et al., 2008). A 
further role of the ACC is in emotional decision-making, where there is a relationship 
between an action and the reinforcement value of its outcome (Rushworth et al., 
2004; Walton et al., 2007). The ACC is involved in updating and integrating recent 
information to existing information on reward value of outcome in terms of predicting 
future outcome (Behrens et al., 2007; Kennerley et al., 2008). 
The present study has two parts: cross-sectional and longitudinal. Cross-sectionally, 
the study aimed to compare the ACC NAA concentration in patients with 
schizophrenia and healthy participants, and to determine their clinical and/or 
neuropsychological correlates; it also explored these effects in Cho and Cr. All 
except for three recent studies that examined these metabolites in patients with 
schizophrenia (Ohrmann et al., 2008; Sanches et al., 2008; Tayoshi et al., 2009) had 
a smaller sample size than our investigation, and none undertook a comprehensive 
examination of metabolite concentration relationships with clinical symptoms and 
neuropsychological functions. We hypothesized that (1) NAA concentration would be 
reduced in patients compared to healthy participants due to impaired neuronal 
function, (2) in patients, NAA concentration would be associated inversely with illness 
duration (Braus et al., 2002; Ende et al., 2000; Theberge et al., 2003) and PANSS 
symptoms (Wood et al., 2007), and (3) NAA concentration would be positively 
associated with neuropsychological measures that involve the ACC, namely working 
memory, conflict detection and decision-making (Behrens et al., 2007; Carter and 
van Veen, 2007; Osaka et al., 2004; Peterson et al., 1999; Smith and Jonides, 1999; 
Walton et al., 2007) both in healthy participants and patients, though such 
relationships may be weaker in patients because they, as mentioned earlier, engage 
the ACC at a less-than-normal level during relevant tasks. We expected that the 
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clinical or neuropsychological correlates of metabolite concentration would be 
attenuated or abolished after controlling for ACC GM concentration (Yamasue et al., 
2002), as GM concentration may influence metabolite availability. 
Longitudinally, the study aimed to determine the effect of cognitive behavioural 
therapy for psychosis (CBTp) on metabolite concentration. A sub-sample of the 
patients in the present investigation went on to receive CBTp in addition to their 
standard care. The study therefore also examined whether (i) baseline metabolite 
concentration predicted symptom change following CBTp+SC and (ii) there was a 
change in metabolite concentration in patients who received CBTp in addition to 
standard care. We hypothesized that in this sub-sample, NAA concentration would 
increase coincident with a reduced level of symptoms following CBTp. 
2. Materials and Method 
2.1. Participants and design 
The study involved 30 patients with schizophrenia and 15 healthy participants all of 
whom underwent MRS of the ACC at study entry. The patient and control groups 
were matched on average for age and gender (Table 2). All patients were assessed 
by a Consultant Psychiatrist (DF) for clinical diagnosis using the Structured Clinical 
Interview for DSM-IV Axis I disorder (First et al., 2002) and symptom severity using 
the Positive and Negative Syndrome Scale (PANSS, Kay et al., 1987). All patients 
were recruited from the South London and Maudsley NHS Foundation Trust as part 
of a larger project investigating the functional neuroimaging correlates and predictors 
of CBTp in psychosis (the MRS component was added to the larger project), were on 
stable doses of antipsychotic medication for at least two years, and on the current 
antipsychotic drug for at least three months prior to taking part. 
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Of the 30 patients at study entry (baseline), 11 patients subsequently received 
CBTp+SC in a specialist clinical service [Psychological Interventions Clinic for 
Outpatients with Psychosis (PICuP), South London and Maudsley NHS Foundation 
Trust (SLAM)] in addition to their standard care and 13 patients continued to receive 
standard care only (SC controls); all of these 24 patients (i) received a rating of > 60 
on the PANSS, (ii) reported at least one positive 'distressing' symptom of 
schizophrenia, and (iii) wished to receive CBTp (if available: only about 10-20% of 
eligible SLAM patients were accepted for CBTp with the existing resources; 
availability was the only criterion that determined whether or not eligible patients 
received CBTp). Eight of 11 CBTp+SC patients and 12 of 13 SC control patients 
were assessed for symptom severity at follow-up, of whom seven and four patients 
respectively underwent MRS at follow-up. Six (of 30) patients had low symptom 
severity at baseline; they were considered to be responsive to antipsychotic 
treatment by their long-term treating clinicians (SC responsive); these patients were 
not followed-up. 
The patients in the CBTp+SC and SC control groups were recruited from the same 
geographical area, were identified by local Consultant Psychiatrists as suitable for 
CBTp, and wished to receive CBTp in addition to their usual care. Allocation to 
CBTp+SC and SC control groups was not randomised, but followed a cohort case-
controlled design. Patients who were referred to and accepted for CBTp by the 
Psychological Interventions Clinic for Outpatients with Psychosis (PICuP), SLAM 
NHS Foundation Trust went into the CBTp+SC group. Others who matched 
demographically (age and number of years in education) and clinically (illness 
duration and PANSS symptoms) as much as possible those accepted for CBTp by 
the PICuP were studied as part of the SC control group over the same interval as the 
CBTp+SC group patients. SC consisted of case management offered by the case 
management team for a particular geographical area. Most patients (80%) were on a 
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single antipsychotic drug (see Table 2). Of the 12 patients on olanzapine, one 
patient also took aripiprazole and a further patient also took trifluoperazine. Of the 
six patients on clozapine, one patient also took quetiapine and a further patient also 
took amisulperide. Of the two patients on haloperidol, one patient was also on 
sulperide and the other patient on pipotiazine. In addition to antipsychotic drug 
treatment, four patients were receiving anti-cholinergics. 
CBTp followed the procedure developed by Fowler and colleagues (1995). Therapy 
sessions were conducted on a weekly or fortnightly basis, as preferred by the patient. 
Patients received an average of 16 sessions. All CBT interventions were 
formulation-driven, and focused on the therapy goals of the patient. The therapists 
were supervised by one of the investigators (EK) who has extensive experience of 
CBTp. 
The study procedures were approved by the ethics committee of the Institute of 
Psychiatry and the South London and Maudsley NHS Foundation Trust, London. All 
participants provided written informed consent to their participation and were 
compensated for their time and travel. 
2.2. Neuropsychological assessments 
All patients and 13 healthy participants were assessed on neuropsychological 
measures (described in Table 1) that are considered to recruit the ACC and found to 
reveal performance deficits in executive function, working/short-term memory, 
attention and emotional decision-making in schizophrenia. 
**** Table 1 about here **** 
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2.3. Magnetic Resonance Spectroscopy: data acquisition and 
processing 
Images were acquired using a 1.5 Tesla GE N/Vi Signa System (General Electric, 
Milwaukee, Wl, USA) at the Maudsley Hospital, South London. A quadrature 
birdcage head coil was used for RF transmission and reception. Initially, a series of 
fast gradient echo scout images were acquired in order to orient subsequent images 
relative to the anterior commissure/ posterior commissure line and the 
interhemispheric fissure. Subsequently, the whole brain was scanned with a 3-D 
inversion recovery prepared fast spoiled GRASS T1-weighted dataset. Chemical 
shift images were acquired from a PRESS excited volume in a 1.5 cm thick slab 
through the anterior commissure, corresponding with the dorsal ACC, with a nominal 
voxel size of 1.5 cm3 (24 * 24 phase-encode steps over a 24 cm FOV). To minimise 
relaxation effects, a short TE of 35 ms was used, and a relatively long TR of 2 
seconds. 
Only metabolite information with a fitting error (percent standard deviation) of <20% 
was included in the final analysis (Ohrmann et al., 2008). Absolute concentrations of 
NAA, Cho and Crwere measured in millimolars in all participants using the LC model 
(McLean et al., 2000; Provencher, 1993). For each MRS voxel, the proportions of 
GM, white matter and cerebrospinal fluid (CSF) were calculated by segmenting the 
Spoiled Gradient Recalled (SPGR) image (Figure 1). This allows correction for CSF 
contamination within each voxel and extrapolation to concentrations for pure GM 
(McLean et al., 2000). Metabolite concentration was calculated as a function of CSF 
concentration within each voxel using the following formula, 
Metabolite value/(1-CSF concentration) 
100 
NAA, Cho and Cr absolute concentration estimates in millimolars are reported rather 
than metabolite peak ratios, such as NAA/Cho, NAA/Cr and Cho/Cr, because 
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absolute concentrations of individual metabolites are not influenced by fluctuations in 
the concentration of the reference metabolite. Metabolite ratios are believed to 
account for alterations in the Cr reference peak which invalidate its usefulness as an 
internal reference for the other metabolite peaks of the proton spectrum (Deicken et 
al., 1997). 
**** Figure 1 about here **** 
2.4. Statistical analysis 
2.4.1. Cross-sectional analysis 
2.4.1.1. Group comparison of metabolite concentration 
Differences between patient (across all patients) and healthy participant groups in 
metabolite concentration and GM concentration, age, years in education, clinical and 
neuropsychological variables were examined using analyses of variance (ANOVA). 
For the neuropsychological variables showing a non-normal distribution (Brixton 
perseverative errors), Mann-Whitney U tests were performed. A chi-squared test 
examined group differences in gender distribution. 
2.4.1.2. Clinical correlates of metabolite concentration 
Pearson and partial correlations controlling for GM concentration, or Spearman 
correlations for clinical variables with a non-normal distribution (antipsychotic 
medication level), were performed between clinical variables and metabolite 
concentrations. The clinical variables were PANSS symptoms, illness duration 
(defined as the difference between the age at onset of psychotic symptoms as 
reported by the patient and where possible confirmed with other sources and age at 
the time of baseline assessments) and antipsychotic medication level (in 
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chlorpromazine equivalents). Spearman correlations were performed to examine the 
relationship between metabolite values and individual PANSS items in those 
subscales that were found to have a significant association with metabolite values. 
2.4.1.3. Neuropsychological correlates of metabolite concentration 
Pearson and partial correlations controlling for GM concentration, or Spearman 
correlations for neuropsychological variables with a non-normal distribution (Brixton 
perseverative errors), were performed between neuropsychological performance 
measures and metabolite concentration in patient and healthy participant groups. 
2.4.1.4. Multiple regression of clinical and/or neuropsychological correlates on 
metabolite concentration 
Significant clinical and/or neuropsychological variables that had a normal distribution 
were entered into the multiple regression model using a stepwise method (to 
estimate the effect of individual predictors on variability of criterion variable) and 
using a forced-entry method (to explain the combined effect of predictors on the 
variability of the criterion variable). 
2.4.2. Longitudinal analysis 
2.4.2.1. Group comparison of metabolite concentration 
Due to the small sample sizes, differences between CBTp+SC, SC control and SC 
responsive patient groups in age, education, clinical variables, and baseline 
metabolite and GM concentrations were examined using non-parametric analyses, 
namely Kruskal-Wallis Test. A chi-squared test determined group differences in 
gender distribution. 
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2.4.2.2. Metabolite concentration as a predictor of symptom change following CBTp 
Spearman correlations were performed in the CBTp+SC patients who were followed-
up (n=8) between baseline metabolite concentrations and residual PANSS symptom 
change scores from baseline to follow-up. 
2.4.2.3. Change in symptom severity and metabolite concentration following CBTp 
Due to the small sample sizes (CBTp+SC, n=7; and SC control, n=4), changes in 
symptom severity, metabolite and GM concentrations from baseline to follow-up in 
the patient groups were examined using Wilcoxon Signed Rank test. 
All analyses were performed in SPSS windows (version 15). Alpha level for testing 
significance of effects was maintained at p< 0.05. We chose not to apply the 
Bonferroni method of adjusting the p value because we expected the size of the 
relationship between MRS values and symptoms / neuropsychological functions to 
be small or at best modest given that symptoms in schizophrenia are unlikely to have 
a single aetiology and successful task performance on most neuropsychological 
tasks would recruit additional brain regions. 
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3. Results 
3.1. Cross-sectional analysis 
3.1.1. Group differences in demographic and neuropsychological 
variables 
Patient and healthy participant groups did not differ in gender and age. Patients had 
fewer years in education and showed deficient performance on most 
neuropsychological measures relative to healthy participants (Table 2). 
**** Table 2 about here **** 
3.1.2. Group differences in metabolite concentration in the ACC 
NAA, Cr and GM concentrations were lower in the patient compared to healthy 
participant group (Table 3). 
**** Table 3 about here **** 
3.1.3. Clinical correlates of metabolite concentration 
NAA concentration correlated inversely with positive symptoms, general 
psychopathology and total symptoms (Table 4). These correlations remained 
significant after controlling for GM. NAA concentration correlated inversely with 
negative symptoms only after controlling for GM. PANSS item-wise correlations 
revealed that NAA concentration was inversely correlated with delusions, 
disorganisation and persecution items of the positive syndrome subscale, passive 
social withdrawal and stereotyped thinking items of the negative syndrome subscale, 
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and somatic concern and preoccupation items of the general psychopathology 
subscale. 
Cho concentration correlated inversely with positive and total symptoms. After 
controlling for GM concentration, Cho concentration correlated with total symptoms, 
but not positive symptoms. Cho concentration correlated inversely with negative 
symptoms at a trend level only after controlling for GM concentration. PANSS item-
wise correlations revealed that Cho concentration was inversely correlated with 
disorganisation and hostility items of the positive syndrome subscale, passive social 
withdrawal item of the negative syndrome subscale and somatic concern item of the 
general psychopathology subscale. Cho concentration correlated positively with 
antipsychotic medication dosage. Cr concentration did not correlate with any clinical 
variable. 
Table 4 about here 
3.1.4. Neuropsychological correlates of metabolite concentration 
Patients: A positive correlation between NAA concentration and working memory as 
assessed by the letter-number test emerged only after controlling for GM 
concentration (Table 5). 
Healthy participants: NAA concentration correlated positively with working memory 
as assessed by the letter-number test and short-term memory as assessed by 
Hopkins verbal learning test, though these correlations were reduced to a trend level 
of significance after controlling for GM concentration (Table 5). Cho concentration 
correlated inversely with short-term memory as assessed by Wechsler Memory Scale 
- Revised (WMS-R) logical memory immediate recall after controlling for GM 
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concentration. Cr concentration correlated inversely with executive function as 
assessed by Brixton perseverative errors. 
**** Table 5 about here **** 
3.1.5. Multiple regression of clinical and/or neuropsychological 
correlates of metabolite concentration 
Patients: In the stepwise regression model with NAA concentration as the criterion 
variable, positive symptoms was a significant predictor (r=-0.489, p=0.006). The 
model explained 21% of the variance in NAA concentration. In the forced-entry 
regression model, the predictors (positive symptoms, general psychopathology and 
letter number test) explained 25% of the variance in NAA concentration. 
Healthy participants: In the stepwise regression model with NAA concentration as 
the criterion variable, short-term memory as assessed by Hopkins verbal learning 
test was a significant predictor (r=0.576, p=0.039). The model explained 27% of the 
variance in NAA concentration. In the forced-entry regression model, the predictors 
(Hopkins verbal learning test and letter-number test) explained 27% of the model. 
3.2. Longitudinal analysis 
3.2.1. Metabolite concentration differences at baseline between patient 
sub-groups 
NAA concentration tended to differ between patient groups at baseline mainly due to 
greater concentration in the low symptom SC responsive group (Table 6). 
15 
Pr -Print
Table 6 about here 
3.3. Metabolite concentration correlates of symptom change following 
CBTp 
In the CBTp+SC group, metabolite concentration at baseline was not associated with 
symptom change following CBTp (Supplementary Table). 
3.4. Symptom severity and metabolite concentration change from 
baseline to follow-up in CBTp+SC and SC control groups 
Positive symptoms improved following CBTp in the CBTp+SC group, while negative 
symptoms tended to deteriorate in the SC control group (Table 7). 
NAA concentration tended to increase in the CBTp+SC group from baseline to 
follow-up (Table 7). 
**** Table 7 about here **** 
4. Discussion 
The present investigation examined the concentrations of NAA, Cho and Cr in the 
ACC and their clinical and neuropsychological correlates in patients with 
schizophrenia and healthy participants (cross-sectional investigation). The study 
also explored whether baseline metabolite concentration predicted symptom change 
following CBTp+SC and whether a reduction in symptoms following CBTp+SC was 
accompanied by higher NAA concentration relative to baseline (longitudinal 
investigation). 
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4.1. Summary of clinical and neuropsychological correlates of 
metabolite concentration (cross-sectional investigation) 
The major findings from the cross-sectional analysis were that in patients: (1) NAA 
concentration was reduced compared to healthy participants, (2) greater NAA 
concentration was associated with a lower level of positive symptoms, general 
psychopathology and better working memory (positive symptoms alone explained 
21% of the variance; total variance explained=25%), and (3) greater Cho 
concentration was associated with a lower level of positive symptoms and higher 
level of antipsychotic medication. In healthy participants the following associations 
were observed: (1) NAA concentration positively with working and short-term 
memory, (2) Cho concentration inversely with short-term memory, and (3) Cr 
concentration inversely with executive function. These findings will be discussed in 
turn. 
4.1.1. Clinical correlates of metabolite concentrations 
The findings of lower ACC NAA concentration in schizophrenia patients (Deicken et 
al., 1997; Ende et al., 2000; Wood et al., 2007) and clinical correlates of NAA 
concentration support previous evidence (Theberge et al., 2003; Wood et al., 2007; 
Yamasue et al., 2002). Our study of a relatively larger sample of patients than most 
previous studies is the first to observe that NAA concentration was inversely 
associated with the severity of positive, negative and general psychopathology 
symptoms based on the three dimensional model of the PANSS (Kay et al., 1987). 
Twenty percent of our patients were SC treatment responsive, giving a wider range 
to symptom scores than earlier studies. Patients who had low symptom severity and 
were considered to have responded sufficiently to their standard (mostly atypical) 
antipsychotic treatment tended to show greater NAA concentration than patients who 
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were symptomatic (baseline comparisons), suggesting that NAA concentration may 
vary as a function of symptom severity and treatment response. 
NAA concentration being a by-product of neurotransmitter turnover (Tranberg et al., 
2004), the symptom severity-metabolite concentration associations may reflect the 
efficiency of neurotransmission. As noted in the Introduction, NAA concentration 
may be an indicator of NMDA function and neuronal longevity (Tranberg et al., 2004). 
NAA efflux is a delayed response to sudden non-physiological decrease in 
extracellular osmolarity and high K+ intra-cellular and NMDA activation (Tranberg et 
al., 2007). Elevated concentration of NAA in the ACC in schizophrenia patients with 
lower level of symptoms may reflect increased turnover of neurotransmitters such as 
dopamine and NMDA. 
Similarly, the association between Cho concentration and total and positive 
symptoms may also reflect improved neurotransmitter function and neuronal integrity 
with milder symptoms. The Cho peak includes soluble membrane phospholipids 
including phosphorylcholine (PCho), glycerophosphocholine (GPCho) and a relatively 
negligible amount of free choline (Ross and Sachdev, 2004). PCho is involved in 
synthesis of the insoluble membrane phospholipids, while GPCho is a product of 
membrane degradation, and free choline is involved in synthesis of the 
neurotransmitter, acetylcholine, as well as in membrane synthesis (Ross and 
Sachdev, 2004). An increase in the Cho peak is associated with an increase in 
membrane breakdown or turnover and myelination (Ross and Sachdev, 2004). The 
positive association between antipsychotic medication dosage and Cho 
concentration, a measure of neuronal membrane turnover (Miller, 1991; Ohrmann et 
al., 2008), suggests that medication level also influences neuronal activity. 
4.1.2. Neuropsychological correlates of metabolite concentration 
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In patients, the finding of an association between greater NAA concentration and 
better working memory supports evidence for the role of frontal lobe function in 
working memory using functional MRI and proton MRS in schizophrenia (Bertolino et 
al., 2000; Callicott et al., 2000; Ohrmann et al., 2007), although this association 
explained only a very small amount (3%) of the variance in NAA concentration that 
was additional to that explained by positive symptoms. 
In the healthy group, greater NAA concentration was associated with better working 
and short-term memory. The ACC is activated during both working and short-term 
memory (Kim et al., 2006; Lenartowicz and Mcintosh, 2005). NAA concentration in 
the frontal lobe white matter was positively associated with working memory in 
healthy children, which may be related to increased number of dendritic processes at 
an early age (Yeo et al., 2000). NAA concentration has a role in neuronal integrity in 
the form of increased myelination and mitochondrial function (Ross and Sachdev, 
2004) and this may facilitate working and short-term memory. 
Greater Cho concentration correlated inversely with short-term memory in the healthy 
group when controlling for GM concentration in the ACC. A negative association 
between Cho concentration in the occipito-parietal white matter and IQ, independent 
of the positive association between NAA concentration and IQ, in healthy individuals 
has been previously reported (Jung et al., 1999). Our findings suggest independent 
metabolite concentration-neuropsychological associations between NAA, Cho and Cr 
in healthy individuals. Greater Cr concentration was associated with poorer 
executive function in the present study. A study of elderly males found negative 
correlations between adjusted Cr in the parietal lobe and various cognitive measures 
including logical memory and verbal memory (Ferguson et al., 2002). The study did 
not include a measure of executive function. Ferguson and colleagues (2002) 
believed that the findings fit with evidence that higher Cr levels are associated with 
cognitive ageing. They proposed that poorer neuropsychological performance in 
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healthy ageing is associated with an increase in Phosphocreatine (PCr) due to a 
reduction in conversion of PCr to Adenosine-tri-phosphate (ATP) for energy. 
Increased Cr concentration may be a marker of decreased brain energy metabolism. 
4.2. Effect of Cognitive Behaviour Therapy for Psychosis on 
metabolite concentration 
Our preliminary investigation of change in metabolite concentration in a small number 
of patients who received CBTp+SC compared to patients who received SC only 
revealed a trend for an increase in NAA concentration with CBTp. This increase in 
NAA was concomitant with improvement in positive symptoms in CBTp+SC patients. 
This finding is consistent with the view that NAA concentration increases with 
alleviation of symptoms as discussed above. Recent functional imaging studies also 
provide evidence for a role of the ACC in responsiveness to CBT in psychosis 
(Kumari et al., 2009) as well as major depression (Costafreda et al., 2009). 
4.3. Limitations and future research 
One of the limitations of the study was that the sample sizes of patients who received 
CBTp+SC or SC only and were clinically assessed and/or scanned at follow-up were 
small. A further limitation was that gender distribution differed between the patient 
groups. Although there was no gender effect within each patient group in the 
metabolite concentrations in the present study, higher ACC glutamine level in male 
compared to female schizophrenia patients has been previously observed (Tayoshi 
et al., 2009). Other effects of gender on ACC function have also been reported, for 
example, reduced ACC glucose metabolism in male chronic patients relative to 
healthy participants and female patients (Fujimoto et al., 2007). The predictive value 
of NAA concentration on symptom change in patients receiving psychological 
treatment or standard care needs to be examined in a larger sample involving 
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sufficient number of both men and women with schizophrenia. Additionally, the role 
of clinical and neuropsychological variables on ACC NAA levels in patients who 
improve with CBTp need to be explored. 
4.4. Conclusions 
Higher NAA and Cho concentrations in the ACC in patients are associated with lower 
symptom severity. Stronger and more consistent associations between metabolite 
concentrations and symptom severity than neuropsychological function suggest that 
metabolite concentration and symptoms may co-fluctuate more strongly. 
Neuropsychological deficits may be more stable (Szoke et al., 2008) and not 
necessarily improve in parallel with symptom improvement (Hughes et al., 2003). 
NAA concentration may yet reflect symptom changes following CBTp and, if 
replicated in future studies, has the potential to provide a useful biological marker of 
clinical response to psychological treatments. 
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Figure legends 
Figure 1. A Spoiled Gradient Recalled (SPGR) brain image in the axial slice in a 
control subject. The square indicates the volume of interest (VOI), 1.5 * 1.5 * 1.5 
cm3 voxel in the anterior cingulate cortex. Within the VOI, each tissue (cerebrospinal 
fluid, gray matter and white matter) was segmented. 
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Table 1. Battery of neuropsychological measures. 
Neuropsychological test Variables used in analysis 
Executive function 
Brixton Test (Burgess and Shallice, 1997) Perseverative errors 
Wisconsin Card Sorting Test (WCST) (Heaton et al., Perseverative errors 
1993) 
Working/short-term memory 
Letter Number Test (Gold et al., 1997) Total number of items correct 
Wechsler Memory Scale - Revised (WMS-R) Logical Unit recall scaled score 
Memory (Wechsler, 1987) - Immediate recall 
Hopkins Verbal Learning Test (Shapiro et al., 1999) Total number of items freely recalled 
Attention 
Continuous Performance Test - Identical Pairs 
(Cornblattetal., 1988) 
Discriminability 
Emotional decision-making 
Iowa Gambling Task (Bechara et al., 1994) Overall learning (Block 5 minus Block 1) 
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Table 2. Demographic, clinical and neuropsychological characteristics of patients and 
healthy participants groups. 
Characteristic 
Gender: male/female (n) 
Age in years 
Years in education 
Illness duration, years 
Symptoms (PANSS) 
Positive 
Negative 
General psychopathology 
Total 
Medication level 
(chlorpromazine equivalents) 
Medication type (n) 
Olanzapine 
Clozapine 
Risperidone 
Aripiprazole 
Flupentixol 
Amisulperide 
Haloperidol 
Neuropsychological function 
Brixton perseverative errors 
WCST perseverative errors 
Letter Number test number 
correct 
WMS logical memory 
immediate unit recalled 
Hopkins total freely recalled 
CPT discriminability 
IGT overall learning 
Patients 
24/6 
mean, s.d. 
36.40, 8.64 
13.83,2.15 
12.98 8.94 
16.93, 3.95 
17.87, 4.52 
31.70,6.39 
66.50, 13.17 
502.67, 327.88 
12 
6 
5 
2 
2 
1 
2 
0.50, 0.78 
18.17, 8.86 
13.80, 3.80 
7.10,2.58 
21.86, 5.38 
0.29, 0.59 
2.80, 11.83 
Healthy 
participants 
13/2 
mean, s.d. 
35.40, 13.34 
15.61, 3.23 
0.31, 0.48 
11.75, 7.51 
16.92, 2.96 
9.69, 3.33 
26.92, 5.17 
1.87, 1.00 
8.92, 14.73 
Test 
Chi-
squared 
ANOVA 
ANOVA 
Mann-
Whitney U 
ANOVA 
ANOVA 
ANOVA 
ANOVA 
ANOVA 
ANOVA 
X (df) 
0.304(1) 
F or z (df) 
0.092(1,43) 
4.555(1,41) 
-0.552(1,41) 
4.870(1,40) 
6.925(1,41) 
7.533(1,40) 
8.122(1,40) 
14.257(1,39) 
2.092(1,41) 
P 
0.581 
0.763 
0.039 
0.648 
0.033 
0.012 
0.009 
0.007 
0.001 
0.156 
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Table 3. ACC metabolite and grey matter concentrations (mean, S.D.) at baseline at 
each voxel in patients and healthy participants. 
Healthy 
participants F (p) 
(n=15) 
8.56,1.39 7.682(0.008) 
1.99,0.36 0.654(0.423) 
7.89,1.02 5.345(0.026) 
61.39,8.58 5.549(0.023) 
CSI variable 
(millimolars) 
NAA 
Cho 
Cr 
Grey matter 
Patient 
(n=30) 
7.42,1.26 
1.90,0.38 
7.03, 1.24 
53.99, 10.51 
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Table 4. Clinical correlates of metabolite concentration at baseline (patients only). 
NAA concentration Cho concentration Cr concentration 
Illness duration 
Antipsychotic 
medication level 
Symptoms (PANSS) 
Positive (P) 
symptoms 
Negative (N) 
symptoms 
General 
psychopathology 
(GP) 
Total 
Individual symptoms 
Delusions (P) 
r or p 
rho 
rho 
Disorganisation (P) r n o 
rho Persecution (P) 
Hostility (P) 
Passive social 
withdrawal (N) 
Stereotyped 
thinking (N) 
Somatic concern 
(GP) 
Preoccupation (GP) r h o 
rho 
rho 
rho 
rho 
r(p) 
-0.059 
(0.756) 
0.197 
(0.298) 
-0.489 
(0.006) 
-0.297 
(0.111) 
-0.416 
(0.022) 
-0.450 
(0.013) 
-0.411 
(0.024) 
-0.525 
(0.003) 
-0.390 
(0.033) 
0.062 
(0.745) 
-0.370 
(0.044) 
-0.422 
(0.020) 
-0.419 
(0.021) 
-0.528 
(0.003) 
rP
1(p) 
0.091 
(0.640) 
-0.430 
(0.020) 
-0.418 
(0.024) 
-0.506 
(0.005) 
-0.512 
(0.004) 
r(p) 
-0.064 
(0.735) 
0.442 
(0.014) 
-0.391 
(0.033) 
-0.287 
(0.124) 
-0.299 
(0.109) 
-0.361 
(0.050) 
-0.342 
(0.064) 
-0.369 
(0.045) 
-0.193 
(0.307) 
0.370 
(0.044) 
-0.393 
(0.032) 
-0.073 
(0.684) 
-0.407 
(0.026) 
-0.201 
(0.287) 
rP
1(p) 
0.045 
(0.817) 
-0.325 
(0.085) 
-0.366 
(0.051) 
-0.341 
(0.070) 
-0.384 
(0.040) 
r(p) 
-0.291 
(0.118) 
0.073 
(0.700) 
-0.308 
(0.098) 
-0.211 
(0.264) 
-0.204 
(0.281) 
-0.263 
(0.160) 
-0.192 
(0.309) 
-0.136 
(0.475) 
-0.068 
(0.719) 
0.163 
(0.390) 
-0.261 
(0.163) 
-0.221 
(0.240) 
-0.129 
(0.496) 
-0.264 
(0.156) 
rP
1(p) 
-0.244 
(0.203) 
-0.262 
(0.170) 
-0.262 
(0.170) 
-0.219 
(0.254) 
-0.266 
(0.163) 
rp
1: partial correlation controlling forGM concentration; P: PANSS positive symptom 
subscale; N: PANSS negative symptom subscale; GP: PANSS general 
psychopathology subscale 
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Table 5. Neuropsychological correlates of metabolite concentration at baseline in 
patients and healthy participants. 
Neuropsychological 
function 
Brixton perseverative 
errors 
WCST perseverative 
errors 
Letter-number test 
number correct 
WMS logical memory Patient 29 
immediate unit 
recalled 
Group 
Patient 
Control 
Patient 
Control 
Patient 
Control 
N 
30 
13 
30 
12 
30 
13 
r or 
rho 
rho 
rho 
Hopkins verbal 
learning test total 
number freely-
recalled 
CPT discriminability 
IGT overall learning 
Control 13 
Patient 29 
Control 13 
Patient 29 
Control 12 
Patient 30 
Control 13 
NAA 
concentration 
r or 
rho r ^ ( p ) 
0.180 
(0.341) 
0.356 
(0.232) 
-0.097 -0.139 
(0.610) (0.473) 
0.271 0.248 
(0.394) (0.461) 
0.303 0.379 
(0.104) (0.043) 
0.557 0.529 
(0.048) (0.077) 
0.301 0.331 
(0.112) (0.085) 
0.330 0.278 
(0.271) (0.382) 
0.127 0.119 
(0.512) (0.564) 
0.576 0.555 
(0.039) (0.061) 
-0.037 0.158 
(0.848) (0.423) 
0.329 0.275 
(0.297) (0.413) 
0.179 0.210 
(0.343) (0.273) 
0.042 0.078 
(0.892) (0.811) 
Cho concentration Cr concentration 
r or 
rho 
-0.198 
(0.293) 
0.356 
(0.232) 
-0.011 
(0.956) 
0.390 
(0.211) 
-0.163 
(0.388) 
0.011 
(0.971) 
0.054 
(0.781) 
-0.453 
(0.120) 
0.181 
(0.348) 
-0.173 
(0.572) 
-0.114 
(0.555) 
-0.209 
(0.514) 
0.026 
(0.891) 
-0.063 
(0.839) 
rP
1(p) 
-0.030 
(0.877) 
0.368 
(0.265) 
-0.160 
(0.407) 
-0.083 
(0.797) 
0.045 
(0.822) 
-0.610 
(0.035) 
0.177 
(0.369) 
-0.330 
(0.295) 
0.016 
(0.936) 
-0.346 
(0.297) 
0.029 
(0.879) 
-0.025 
(0.939) 
r or 
rho 
0.331 
(0.074) 
0.579 
(0.038) 
-0.102 
(0.592) 
-0.225 
(0.483) 
-0.130 
(0.493) 
0.156 
(0.611) 
-0.017 
(0.932) 
-0.022 
(0.946) 
0.269 
(0.159) 
0.277 
(0.36) 
0.003 
(0.986) 
0.207 
(0.519) 
0.062 
(0.747) 
-0.225 
(0.461) 
rP
1(p) 
-0.116 
(0.550) 
0.312 
(0.35) 
-0.124 
(0.523) 
-0.030 
(0.927) 
-0.025 
(0.898) 
-0.267 
(0.401) 
0.265 
(0.173) 
0.061 
(0.851) 
0.088 
(0.656) 
0.006 
(0.986) 
0.064 
(0.742) 
-0.169 
(0.600) 
rp : partial correlation controlling forGM concentration 
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Table 6. Demographic, clinical and metabolite concentration characteristics at 
baseline of CBTp+SC (n=11), SC control (n=13), and SC responsive (n=6) patients. 
Characteristic 
Gender: male/female (n) 
Age in years 
Years in education 
Illness duration, years 
Symptoms (PANSS) 
Positive 
Negative 
General psychopathology 
Total 
Medication level 
Metabolite concentration 
NAA 
Cho 
Cr 
Grey matter 
CBTp+SC 
6/5 
mean, s.d. 
34.64, 
14.45, 
11.94, 
17.45, 
18.18, 
32.27, 
67.91, 
564.42, 
7.65, 
1.92, 
6.89, 
57.66, 
8.62 
2.46 
8.60 
2.95 
4.98 
6.75 
12.87 
303.17 
0.92 
0.60 
1.40 
10.71 
SC control 
12/1 
mean, s.d. 
37.46, 8.77 
13.46, 1.76 
13.77, 9.70 
19.15,2.64 
19.23, 3.86 
34.0, 5.49 
72.39, 9.94 
500.55, 394.78 
6.85, 1.43 
1.86, 0.24 
6.87, 0.95 
51.17, 11.36 
SC responsive 
( 
37.33, 
13.77, 
13.17, 
11.17, 
14.33, 
25.67, 
51.17, 
394.05, 
8.23, 
1.94, 
7.48, 
53.37, 
3/0 
9.42 
2.4 
9.28 
1.72 
3.61 
3.83 
7.78 
207.59 
0.91 
0.18 
1.60 
7.14 
X 
7.185 
0.745 
1.156 
0.303 
14.644 
5.779 
6.775 
9.512 
1.787 
5.313 
0.493 
1.047 
1.096 
P 
0.028 
0.689 
0.561 
0.860 
0.001 
0.056 
0.034 
0.009 
0.409 
0.070 
0.781 
0.592 
0.578 
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Table 7. Symptoms, metabolite and grey matter concentration (mean, s.d.) at baseline and follow-up in CBTp+SC and SC control groups. 
CSI variable CBTp+SC (n=7) SC control (n=4) 
Baseline Follow-up z (p) Baseline Follow-up z (p) 
Clinical symptoms 
Positive symptoms 18.14(2.34) 15.67(3.50) -2.032(0.042) 19.25(2.22) 18.25(2.63) -0.365(0.715) 
Negative symptoms 18.57(5.71) 15.67(2.34) -0.813(0.416) 18.75(4.99) 22.00(6.16) -1.841(0.066) 
General psychopathology 32.00(5.66) 27.33(4.97) -1.382(0.167) 35.00(6.68) 32.75(5.91) -0.535(0.593) 
Total symptoms 68.71(12.27) 58.67(10.17) -1.472(0.141) 73.00(10.42) 73.00(13.64) -0.001(1.000) 
Metabolite concentration 
NAA 7.65(0.68) 8.31(0.77) -1.859(0.063) 7.40(0.69) 7.04(0.38) -1.826(0.068) 
Cho 1.85(0.42) 1.93(0.2) -0.507(0.612) 1.90(0.18) 2.01(0.08) -0.730(0.465) 
Cr 6.79(0.89) 7.25(1.03) -0.845(0.398) 7.02(0.16) 7.36(0.99) -0.730(0.465) 
Grey matter 57.06(11.55) 58.60(8.51) -0.338(0.735) 53.53(5.49) 53.24(3.35) -0.365(0.715) 
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Supplementary Table. Correlation between metabolite concentration at baseline and 
residual symptom change following CBTp. 
CSI variable CBTp+SC (n=8) 
NAA Cho Cr 
rho (p) rho (p) rho (p) 
0.357 0.310 <0.001 
(0.385) (0.456) (1.000) 
-0.262 0.190 -0.167 
(0.531) (0.651) (0.693) 
-0.252 0.611 0.228 
(0.548) (0.108) (0.588) 
-0.071 0.238 -0.071 
(0.867) (0.570) (0.867) 
Positive symptoms 
Negative symptoms 
General psychopathology 
Total symptoms 
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Appendix 1. Summary of magnetic resonance spectroscopy studies on the anterior cingulate cortex (ACC) in schizophrenia patients. 
Publication 
Deicken et 
al. (1997) 
Ende et al. 
(2000) 
Braus et al. 
(2001; 
2002) 
Participants 
Schizophrenia patients (n=26; 9 
on atypical and 17 on typical) 
Healthy participants (n=16) 
Schizophrenia patients (n=19; 
10 on atypical and 9 on typical) 
Healthy participants (n=16) 
Schizophrenia patients (11 on 
atypical and 10 on typical) 
Measures 
NAA, Cho and Cr, illness duration, 
antipsychotic medication dose 
NAA, Cho and Cr, age, illness duration. 
NAA, Cho and Cr, illness duration, 
duration on atypical antipsychotic 
medication, WCST 
Results 
Patients had lower NAA concentration compared to healthy 
participants. 
No significant group differences or lateralized asymmetries for 
Cho or Cr. No significant correlations between NAA and either 
illness duration or antipsychotic medication dose. 
Patients had lower NAA concentration compared to healthy 
participants. 
Patients receiving typical medication (but not atypical) had 
lower NAA concentration than healthy participants. 
NAA concentration was inversely correlated with age in 
patients and healthy participants, and with illness duration 
(corrected for age) in patients. 
Patients receiving typical antipsychotics had lower NAA 
concentration than patients receiving atypical antipsychotics. 
NAA concentration was inversely correlated with illness 
duration and positively with duration on atypical antipsychotic 
medication. NAA concentration was inversely correlated with 
WCST perseverative errors. 
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Appendix 1 continued 
Publication 
Goff et al. 
(2002) 
Yamasue et 
al. (2002) 
Participants 
Schizophrenia patients (n=17; 
of whom 10 switched from 
conventional to olanzapine and 
had MRS at baseline and 8-
week follow-up). 
Schizophrenia patients (n=15; 
all on typical) 
Healthy participants (n=13) 
Measures 
Glu/Cr ratio, SANS 
NAA, Cho and Cr; grey matter volume; 
age, height, body weight, socio-
economic status, parental socio-
economic status, years of education, 
PANSS, onset of illness, illness 
duration, antipsychotic medication dose. 
Results 
Glu/Cr ratio was increased by 12.5% (non-significant) following 
switch to olanzapine. 
Patients who improved on SANS symptoms had greater Glu/Cr 
ratio (45.8%) compared to patients who deteriorated on SANS 
symptoms (20.8%). 
No significant correlation between SANS total and change in 
Glu/Cr ratio after switch. 
Patients had lower NAA/Cho ratio and greater Cho/Cr ratio 
compared to healthy participants after controlling for grey 
matter volume. 
NAA/Cho ratio was positively correlated with grey matter 
volume in patients, not healthy participants. NAA/Cho ratio 
was inversely correlated with PANSS blunted affect score. 
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Appendix 1 continued 
Publication 
Theberge 
et al. (2004; 
2002) 
Theberge 
et al. (2003) 
Wood et al. 
(2007) 
Participants 
First-episode neuroleptic naive 
schizophrenia patients (n=21) 
Healthy participants (n=21) 
Schizophrenia patients (n=21; 
atypical n=7, both n=1, typical 
n=13) 
Healthy participants (n=21) 
Schizophrenia male patients 
(n=15; 13 atypical, 2 medication 
free) 
Healthy male participants 
(n=14) 
Measures 
Analysis in Theberge 2002 
NAA, Cho, Cr, Glu, Gin, ml in left ACC, 
SANS, SAPS 
Analysis in Theberge 2004 
NAA and Cho in left ACC 
DUP, DUI, DPS 
NAA, Cho, Cr, Glu, Gin, ml in left ACC, 
duration of illness 
NAA and Glx in dorsal and rostral 
regions, PANSS five factors, illness 
duration 
Results 
From Theberae2002 
Patients had greater Gin concentration compared to healthy 
participants. 
Metabolite concentrations were not correlated with SANS or 
SAPS. 
From Theberge2004 
NAA concentration was positively correlated with DUP and 
inversely with DPS at trend level. Cho concentration was 
positively correlated with DUP. 
Glu and Gin concentrations were greater in patients than 
healthy participants. 
NAA concentration was inversely correlated with duration of 
positive symptoms. 
Patients had lower NAA concentration compared to healthy 
participants. 
Right dorsal Glx was inversely correlated with illness duration. 
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Appendix 1 continued 
Publication 
Ohrmann et 
al. (2008) 
Sanches et 
al. (2008) 
Tayoshi et 
al. (2009) 
Participants 
Schizophrenia patients (n=43, 
all on atypical) 
Healthy participants (n=37) 
Schizophrenia patients (n=37) 
Healthy participants (n=37) 
Long-term schizophrenia (n=30; 
antipsychotic medication type 
not reported) 
Healthy participants (n=25) 
Measures 
NAA, Cho, Cr, Glx, WCST learning 
potential 
NAA/(Cho+Cr) ratio in left and right 
anterior middle frontal gyrus, ACC and 
perirolandic area (reference), basal skin 
conductance and skin conductance 
response to auditory stimuli of 1 second 
tones of 80dB. Patients and healthy 
participants classified into skin 
conductance responders (2 S.D. below 
mean skin conductance in healthy 
participants) and non-responders. 
NAA, Cho, Cr, Glu, Gin, ml 
Gender, PANSS total and subscales, 
duration of illness, duration of therapy, 
antipsychotic dosage, benzodiazepine 
dose 
Results 
No difference in metabolite concentration between patients and 
healthy participants. 
NAA and Glx concentrations were positively associated with 
WCST learning potential 
NAA/(Cho+Cr) ratio was lower in patients than healthy 
participants in the anterior middle frontal gyrus and ACC 
bilaterally. NAA/(Cho+Cr) ratio did not differ between skin 
conductance response groups based on skin conductance 
response to auditory stimuli. Basal skin conductance non-
responders patients had lower NAA/(Cho+Cr) ratio than 
healthy participants in left and right ACC. 
Patients had lower Glu and ml concentration compared to 
healthy participants. Male patients had lower NAA, Cr, Glu and 
ml concentration than male healthy participants. Males had 
greater Gin concentration compared to females. 
Metabolite concentration was not correlated with symptoms or 
other clinical variables. 
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Appendix 1 continued 
Publication 
Ongur et al. 
(2009) 
Participants 
Schizophrenia patients (n=15) 
Bipolar disorder patients (n=15) 
Healthy participants (n=22) 
Measures 
Cr in ACC (hypothesized area) and 
parietal-occipital cortex (reference 
area), MADRS, PANSS, YMRS 
Results 
Patients had lower Cr than healthy participants in both ACC 
and parietal-occipital cortex. 
No significant correlations between Cr concentration and 
clinical measures. 
ACC: anterior cingulate cortex, Cho - Choline, Cr - Creatine/Phosphocreatine, DPS - duration of psychotic symptoms, DUI - duration of 
untreated illness, DUP - duration of untreated psychosis, Gin - Glutamine, Glu - Glutamate, Glu/Cr ratio, SANS - Schedule for the 
Assessment of Negative Symptoms, Glx - Glutamate+Glutamine, MADRS - Montgomery Asberg Depression Rating Scale, ml - myo-
inositol, NAA: N-acetyl aspartate, PANSS - Positive and Negative Syndrome Scale, SAPS: Schedule for the Assessment of Positive 
Symptoms, WCST - Wisconsin Card Sorting test, YMRS - Young Mania Rating Scale. 
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Figure(s) 
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